Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979029 | 0.86 | LMNA (0.43) | PTGIRLMNAALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL9699072 | 0.86 | LMNA (0.44) | LMNAALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL6978072 | 0.86 | LMNA (0.44) | LMNAALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL6978928 | 0.86 | LMNA (0.44) | PTGIRLMNAALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL6979329 | 0.85 | ALDH1A1 (0.41) | PTGIRALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL6967825 | 0.85 | GRM2 (0.54) | LMNAALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL12695869 | 0.84 | MAPT (0.48) | LMNAALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL5100424 | 0.83 | PTGIR (0.46) | PTGIRCA2 | |
| SCHEMBL2190445 | 0.83 | PTGIR (0.46) | PTGIRCA2 | |
| SCHEMBL3208378 | 0.83 | CYP2D6 (0.45) | PTGIRLMNAALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2177513-B1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20140357630-A1 | Phenylacetic Acid Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-12-04 | — | — | US | disclosed |
| US-20140357630-A1 | Phenylacetic Acid Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-12-04 | — | — | US | disclosed |
| US-8809524-B2 | Phenylacetic acid compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809524-B2 | Phenylacetic acid compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20130225808-A1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225808-A1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-8476266-B2 | Phenylacetic acid compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20130028887-A1 | PHENYLACETIC ACID COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-1666473-B1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-02 | — | — | EP | disclosed |
| EP-2177513-A1 | PHENYLACETIC ACID COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177513-A1 | PHENYLACETIC ACID COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20100029631-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7601712-B2 | Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7351705-B2 | Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20070004716-A1 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1666473-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1486491-A1 | CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225808-A1 | PHENYLACETIC ACID COMPOUND | PC, PAH, PDHA2 | PTGIR 3123/4885LMNA 2910/4885ALDH1A1 64/4885 |
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | PTGIS, IDO1, IDO2 | PTGIR 4/4885LMNA 4422/4885ALDH1A1 1468/4885 |
| US-20100029631-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | GPR17, CYSLTR1, KIT | PTGIR 6/4885LMNA 4266/4885ALDH1A1 368/4885 |
| US-20130028887-A1 | PHENYLACETIC ACID COMPOUND | PC, PAH, PDHA2 | PTGIR 3123/4885LMNA 2910/4885ALDH1A1 64/4885 |
| US-20070004716-A1 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | GPR17, CYSLTR1, KIT | PTGIR 6/4885LMNA 4266/4885ALDH1A1 368/4885 |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | UACA, CPA3, HCAR1 | PTGIR 30/4885LMNA 4217/4885ALDH1A1 588/4885 |
| US-20140357630-A1 | Phenylacetic Acid Compound | PC, PAH, PDHA2 | PTGIR 3123/4885LMNA 2910/4885ALDH1A1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.